<DOC>
	<DOCNO>NCT00135902</DOCNO>
	<brief_summary>A recently complete trial weekly injection 17 alpha hydroxyprogesterone caproate ( 17P ) find significant effectiveness 17P prevent recurrent preterm birth . However , group receive 17P trial still high rate preterm birth . Several report show dietary supplementation fish oil , rich Omega-3 fatty acid , reduces risk preterm birth . This trial test whether add Omega-3 supplement 17P therapy potential reduce risk preterm birth woman previously spontaneous preterm delivery . The trial compare Omega-3 fatty acid placebo woman receive 17P therapy . The hypothesis test : `` Among woman high risk preterm birth receive weekly injection 17P , addition Omega-3 nutritional supplement reduce rate preterm birth . ''</brief_summary>
	<brief_title>Omega-3 Fatty Acid Supplementation Prevent Preterm Birth High Risk Pregnancies</brief_title>
	<detailed_description>Preterm birth lead cause perinatal mortality morbidity . In recently complete trial weekly injection 17 alpha hydroxyprogesterone caproate ( 17P ) , National Institute Child Health Human Development ( NICHD ) Maternal Fetal Medicine Units ( MFMU ) Network find treatment significantly beneficial prevention recurrent preterm birth . Other study show fish oil supplementation reduce risk preterm birth . The purpose study determine whether Omega-3 , polyunsaturated fatty acid nutritional supplement , addition injection 17P , decrease rate preterm birth woman risk . This study randomize , double-masked clinical trial two study arm : daily supplement Omega-3 capsule contain 800 mg DHA 1200 mg EPA daily supplement match placebo . All patient also receive weekly injection 17P . Eight hundred pregnant woman history previous preterm delivery recruit study . After successfully complete compliance run-in , begin early 15 week gestation , patient randomize begin treatment 16 22 week gestation . They remain study drug 36 week 6 day delivery , whichever occur first . Blood drawn randomization monthly visit fall 25-29 week gestation test compliance , analyze genetic polymorphism determine whether Omega-3 affect production inflammatory cytokine .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>Documented history previous singleton spontaneous birth Singleton pregnancy Gestational age randomization 16 22 week Major fetal anomaly demise Regular intake fish oil supplement Daily use nonsteroidal antiinflammatory agent Allergy fish fish product Gluten intolerant Heparin use know thrombophilia Hemophilia Planned termination Current hypertension current use antihypertensive medication Type D , F R diabetes Maternal medical complication Current plan cerclage Illicit drug alcohol abuse current pregnancy Delivery nonNetwork hospital Participation another pregnancy intervention study Participation trial previous pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Preterm birth</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Pregnancy</keyword>
</DOC>